Sun Pharmaceutical

Sun Pharma may acquire Zenotech Laboratories Ltd

Sun Pharma may acquire Zenotech Laboratories Ltd

Sun Pharma, which recently proposed a $4-billion deal to merge Ranbaxy Labs with itself, will also make an open offer to acquire around 28 per cent stake in Zenotech Laboratories Ltd.

In a regulatory filing, Sun Pharma said it could buy nearly 96 lakh shares of Hyderabad-based Zenotech, amounting to 28.1 per cent stake, for Rs 18.42 crore or Rs 19 per share. Ranbaxy owns 46.79 per cent stake in Zenotech.

The pharma giant added that the merger of Ranbaxy into it would result in Sun Pharma's indirectly acquiring Ranbaxy's 46.79 per cent voting rights over Zenotech.

Sun Pharma to acquire Ranbaxy in $3.2 billion all-share deal

Sun Pharma to acquire Ranbaxy in $3.2 billion all-share deal

Mumbai-based Sun Pharmaceutical Industries Ltd has confirmed that it will acquire beleaguered Ranbaxy Laboratories Ltd in a $3.2 billion all-stock deal.

Following its merger with Ranbaxy, Sun Pharma will become India's biggest pharmaceutical firm and the world's fifth biggest generic drugs maker.

FDA imposes import alert on Sun Pharma’s Gujarat facility

FDA imposes import alert on Sun Pharma’s Gujarat facility

Sun Pharmaceuticals Ltd has joined the list of top Indian drugmakers facing the heat of the Food & Drug Administration's annoyance as the U. S. regulator has imposed an import alert on its Karkhadi, Gujarat-based plant.

The drugmaker said in a statement that the Gujarat plant was a dedicated cephalosporin facility, and the import ban was a follow-up to an inspection of the facility by the FDA late last year. The regulator imposed the ban due to alleged non-compliance of current good manufacturing practice regulations.

Sun Pharma raises revenue growth outlook to 25%

Sun Pharma raises revenue growth outlook to 25%

Indian drug-maker Sun Pharmaceutical Industries Limited (Sun Pharma) has reported a bigger-than-expected year-on-year rise in September quarter profit, along with a hike in its revenue growth outlook for current fiscal.

Late on Wednesday, Sun Pharma announced that its net profit jumped nearly 3.5 times to Rs 1,559.79 crore in the July-September quarter of current fiscal, while net sales jumped at an impressive rate of 46 per cent Rs 4,192.05 crore. In the corresponding quarter of the last fiscal, the company had reported net sales of Rs 2,857.24 crore.

Sun Pharma reports better-than-expected Q4 earnings, shares jump

Sun Pharma reports better-than-expected Q4 earnings, shares jump

Sun Pharmaceutical Industries Ltd, India’s No. 3 drug maker, on Tuesday announced a more-than-expected increase in quarterly profit and forecast a robust sales growth for the currently fiscal.

Sun Pharma announced that its consolidated net profit jumped 23 per cent year-on-year to Rs 1,012 crore in the quarter ended March 31, 2013.

Indian Market Opens Positive on Wednesday; Asian Markets Strong

Kidnapped oil workers freed in ColombiaIndian Stock Market opened positive on day after Christmas with Capital Goods, Consumer Durables and Metal counters trading strong. Japanese Yen has hit 20 month low against USD and Euro and stock prices of major Japanese exporters were trading higher. Other Asian markets were trading positive.

Merck close to strategic deal with Sun Pharma

Merck close to strategic deal with Sun PharmaSun Pharmaceutical Industries announced to close a strategic marketing partnership with US-based drug multinational Merck and Company Inc. in the domestic market which has reported gains for Sun Pharmaceutical Industries. Its shares rose 1.27% to Rs. 447 at 9:38 IST.

Sun Pharma net falls 26%

Sun Pharma net falls 26%

Sun Pharmaceutical Industries' has announced its annual financial results for the fiscal year 2009-10. The net profit of the company has fallen down by 26% for the year that ended in 31st March, 2010.

The net profit of the firm was reported to be Rs 1,351 crore for the preceding financial year. So this year was not so impressive for the leading pharmaceutical company of the country. Form a mammoth net profit posted last year, it has declined to almost 26% this year.

Franklin Templeton relieves Sun Pharma

Franklin Templeton relieves Sun PharmaPharmaceutical major Sun Pharmaceutical has finally got some relief after Franklin Templeton has finally decided to withdraw the appeal against the company. Franklin Templeton was a co- appellant along with Israeli pharmaceutical major Taro Pharma against Sun Pharma.

The news helped the shares of Sun Pharma to upsurge by 5.62% to Rs. 1538.80 on the BSE.

Strattera Gains Tentative Approval from FDA

Strattera Gains Tentative Approval from FDAAs confirmed by Mumbai based Sun Pharmaceutical Industries on Thursday, the drug-maker's generic treatment for mental disorders, Strattera has managed to get a tentative approval from the US Food and Drug Administration.